×
About 9,445 results

ALLMedicine™ Somatostatin Center

Research & Reviews  3,223 results

Somatostatin interneurons exhibit enhanced functional output and resilience to axotomy ...
https://doi.org/10.1016/j.nbd.2022.105801
Neurobiology of Disease; Harris AC, Jin XT et. al.

Jun 27th, 2022 - Mild traumatic brain injury (mTBI) gives rise to a remarkable breadth of pathobiological consequences, principal among which are traumatic axonal injury and perturbation of the functional integrity of neuronal networks that may arise secondary to ...

Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing Syndrome
https://clinicaltrials.gov/ct2/show/NCT02019706

Jun 24th, 2022 - Between 10% and 15% of patients with endogenous hypercortisolism (Cushing syndrome) have ectopic (non-pituitary) production of adrenocorticotropin hormone (ACTH) that causes cortisol excess. In approximately 50% of these patients, the tumoral sour...

The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
https://clinicaltrials.gov/ct2/show/NCT04927416

Jun 24th, 2022 - The study is designed to identify the patients with metastatic radioactive iodine (RAI) non-avid or non-responsive thyroid cancer RAI non-responsive Hurthle cell thyroid cancer (HTC), differentiated thyroid cancer (DTC) and metastatic medullary th...

see more →

Guidelines  10 results

ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
https://doi.org/10.1097/RLU.0000000000004182
Clinical Nuclear Medicine; Love C, Desai NB et. al.

May 5th, 2022 - This practice parameter (PP) for Lutetium-177 (Lu-177) DOTATATE peptide receptor radionuclide therapy (PRRT) aims to guide authorized users in selection of appropriate adult candidates with gastroeneropancreatic neuroendocrine tumors (GEP-NETs) fr...

ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
https://doi.org/10.1097/COC.0000000000000903
American Journal of Clinical Oncology; Love C, Desai NB et. al.

May 5th, 2022 - This practice parameter (PP) for Lutetium-177 (Lu-177) DOTATATE peptide receptor radionuclide therapy (PRRT) aims to guide authorized users in selection of appropriate adult candidates with gastroeneropancreatic neuroendocrine tumors (GEP-NETs) fr...

International consensus statement on the diagnosis and management of autosomal dominant...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136168
Nature Reviews. Nephrology; Gimpel C, Bergmann C et. al.

May 24th, 2019 - These recommendations were systematically developed on behalf of the Network for Early Onset Cystic Kidney Disease (NEOCYST) by an international group of experts in autosomal dominant polycystic kidney disease (ADPKD) from paediatric and adult nep...

Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expe...
https://doi.org/10.1093/annonc/mdv041
Annals of Oncology : Official Journal of the European Soc... Caplin ME, Baudin E et. al.

Feb 4th, 2015 - Pulmonary carcinoids (PCs) are rare tumors. As there is a paucity of randomized studies, this expert consensus document represents an initiative by the European Neuroendocrine Tumor Society to provide guidance on their management. Bibliographical ...

Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (...
https://doi.org/10.1055/s-0034-1377875
Endoscopy Dumonceau JM, Andriulli A et. al.

Aug 26th, 2014 - This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE). It addresses the prophylaxis of post-endoscopic retrograde cholangiopancreatography (post-ERCP) pancreatitis. Main recommendations 1 ESGE recomme...

see more →

Drugs  21 results see all →

Clinicaltrials.gov  345 results

Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing Syndrome
https://clinicaltrials.gov/ct2/show/NCT02019706

Jun 24th, 2022 - Between 10% and 15% of patients with endogenous hypercortisolism (Cushing syndrome) have ectopic (non-pituitary) production of adrenocorticotropin hormone (ACTH) that causes cortisol excess. In approximately 50% of these patients, the tumoral sour...

The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
https://clinicaltrials.gov/ct2/show/NCT04927416

Jun 24th, 2022 - The study is designed to identify the patients with metastatic radioactive iodine (RAI) non-avid or non-responsive thyroid cancer RAI non-responsive Hurthle cell thyroid cancer (HTC), differentiated thyroid cancer (DTC) and metastatic medullary th...

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
https://clinicaltrials.gov/ct2/show/NCT04086485

Jun 24th, 2022 - Background: Neuroendocrine tumors (NETs) of the gastrointestinal tract and pancreas are a rare and heterogeneous, but clinically important, group of neoplasms with unique tumor biology, natural history, and clinical management issues. While the tr...

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
https://clinicaltrials.gov/ct2/show/NCT03206060

Jun 24th, 2022 - Background: Pheochromocytomas/paragangliomas (PHEOs/PGLs) are rare tumors arising from neural crest tissue that can develop in sympathetic and parasympathetic paraganglia throughout the body. Those arising in the adrenal gland are called PHEOs whi...

Post-Authorization Long-Term Safety Study of LUTATHERA
https://clinicaltrials.gov/ct2/show/NCT03691064

Jun 23rd, 2022 - To assess the incidence and nature of potential long-term safety outcomes (follow-up period up to 7 years) in patients with unresectable or metastatic, well-differentiated, somatostatin receptor positive gastroenteropancreatic neuroendocrine tumou...

see more →

News  177 results

Depression Biomarkers: Which Ones Matter Most?
https://www.medscape.com/viewarticle/973347

May 3rd, 2022 - Multiple biomarkers of depression involved in several brain circuits are altered in patients with unipolar depression. The first comprehensive meta-analysis of all biomarkers quantified to date in cerebrospinal fluid (CSF) of individuals with unip...

Early Promise for New Agent in Congenital Hyperinsulinism in Kids
https://www.medscape.com/viewarticle/972526

Apr 21st, 2022 - An investigational glucagon-like peptide-1 (GLP-1) antagonist, exendin-(9-39), prevents fasting and protein-induced hypoglycemia among children with congenital hyperinsulinism, new data suggest.   Results from the open-label crossover phase 2 tria...

Oral Octreotide Shows Promise as Alternative to Injections for Acromegaly
https://www.medscape.com/viewarticle/966233

Jan 10th, 2022 - NEW YORK (Reuters Health) - Many patients with acromegaly may do as well on oral octreotide treatment as they do on injectable somatostatin receptor ligands (iSRLs), an industry-sponsored phase-3 trial suggests. Oral octreotide is the first oral m...

XmAb18087 Shows Encouraging Preliminary Activity in NETs
https://www.onclive.com/view/xmab18087-shows-encouraging-preliminary-activity-in-nets

Jan 3rd, 2022 - Preliminary data from the phase 1 Duet-1 study of XmAb18087 (tidutamab), a humanized, anti–somatostatin receptor 2 (SSTR2), anti–CD3 bispecific antibody, demonstrated a disease control rate (DCR) of 43% across dose levels in patients with neuroend...

Influx of Therapies in NETs Prompts Questions Over Combinations and Sequencing
https://www.onclive.com/view/influx-of-therapies-in-nets-prompts-questions-over-combinations-and-sequencing

Nov 19th, 2021 - Tyrosine kinase inhibitors (TKIs), hypoxia-inducible factor 2α (HIF-2α) inhibitors, and peptide receptor radiotherapy are generating excitement in the field of neuroendocrine tumors (NETs), explained Diane Reidy-Lagunes, MD. However, until more de...

see more →

Patient Education  2 results see all →